Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive Signature of Benralizumab Response
2020-002165-34Phase 4Active
- Sponsor
- CHU de Nantes
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of benralizumab in severe asthma and eosinophilic asthma (EA), sponsored by CHU de Nantes. Primary endpoint: Early blood gene expression signature predicting benralizumab response. Started Sep 2020; status: active.
02
Drugs
benralizumab
03
Conditions
severe asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on 2020-002165-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002165-34.